Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1287 - Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)?

Date

10 Sep 2017

Session

Poster display session

Presenters

Alexey Tryakin

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

A. Tryakin1, M. Fedyanin1, J. Sergeev2, A. Bulanov1, B. Akhmedov3, T. Zakharova4, V. Matveev5, I. Fainstein2, A. Garin1, S. Tjulandin1

Author affiliations

  • 1 Clinical Pharmacology And Chemotherapy, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 2 Radiosurgery, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 3 Thoracic Surgery, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 4 Pathology, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 5 Urology, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
More

Resources

Abstract 1287

Background

Three-four cycles of BEP are commonly recognized as a standard 1-st line ChT in aNSGCT. However, there were no trials studying optimal cycles numbers in this setting, especially in case of unfavorable TTN of tumor markers. We performed retrospective single center analysis to evaluate if pts with unfavorable TTN of tumor markers may benefit with prolongation of induction ChT.

Methods

Inclusion criteria were as follows: (1) ChT-naïve aNSGCT pts treated with etoposide- and cisplatin-based chemotherapy; (2) AFP and hCG levels available at days 0 and 18-22 of cycle 1 to calculate TTN (Fizazi K., JCO 2004). Pts who received less than “standard” number of cycles (3xBEP or 4xEP for IGCCCG good risk, 4xBEP for intermediate and poor risk) for any reason were excluded from the analysis. Cox` regression multivariate analysis was also performed. TTN was calculated by K.Fizazi’s methodic (JCO 2004).

Results

From 1987 to 2011 952 pts with aNSGCT received 1-st line ChT. 584 pts matched the inclusion criteria. Unfavorable TTN had 24 (11%), 61 (41%) and 122 (84%) of pts with good, intermediate and poor IGCCCG risk, respectively. More than standard number of cycles received 199 pts. Prolongation of ChT did not result in significant improvement of OS in any IGCCCG prognostic groups irrespectively of TTN (Table).Table:

914P

IGCCCG risk groupTTN/# of cyclesN pts5-y OS, %p (HR, 95%CI)
Goodfavorable/standard17692%0,44
favorable/>standard4298%(HR 0,63, 0,23-1,89)
unfavorable/standard1593%0,65
unfavorable/> standard978%(HR 1,48, 0.24-10.48)
Intermediatefavorable/standard12788%0,14
favorable/>standard2080%(HR 2,1, 0,73-9,38)
unfavorable/standard3281%0,66
unfavorable/> standard2986%(HR 0,78, 0.25-2.41)
Poorfavorable/standard1291%0,17
favorable/>standard10100%(HR 0,14, 0.01-2.27)
unfavorable/standard2365%0,55
unfavorable/> standard8972%(HR 0,79, 0.33-1.79)

Conclusions

Prolongation of 1-st line ChT beyond standard number of cycles does not improve outcome of pts with unfavorable TTN of tumor markers.

Clinical trial identification

Legal entity responsible for the study

Alexey Tryakin

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.